

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

PHARMACYTE BIOTECH, INC.

(Name of Issuer)

Common Stock, \$0.0001 par value

(Title of Class of Securities)

71715X203

(CUSIP Number)

12/31/2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 71715X203

1	Names of Reporting Persons Ayrton Capital LLC
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 774,100.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 774,100.00
	8	Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 774,100.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 9.9 %	
12	Type of Reporting Person (See Instructions) IA	

SCHEDULE 13G

CUSIP No.	71715X203
-----------	-----------

1	Names of Reporting Persons Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization CAYMAN ISLANDS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 774,100.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 774,100.00
	8	Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 774,100.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	

11	Percent of class represented by amount in row (9) 9.9 %
12	Type of Reporting Person (See Instructions) CO

SCHEDULE 13G

CUSIP No.	71715X203
-----------	-----------

1	Names of Reporting Persons Waqas Khatri
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 774,100.00
	6 Shared Voting Power 0.00
	7 Sole Dispositive Power 774,100.00
	8 Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 774,100.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>
11	Percent of class represented by amount in row (9) 9.9 %
12	Type of Reporting Person (See Instructions) IN

SCHEDULE 13G

Item 1.

- (a) **Name of issuer:**
PHARMACYTE BIOTECH, INC.
- (b) **Address of issuer's principal executive offices:**
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, 89169

Item 2.

(a) **Name of person filing:**

- (i) Ayrton Capital LLC;
- (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B; and
- (iii) Waqas Khatri

(b) **Address or principal business office or, if none, residence:**

(i) Ayrton Capital LLC,
55 Post Rd West, 2nd Floor
Westport, CT 06880;

(ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B,
Suite #7 Grand Pavilion Commercial Centre,
802 West Bay Road,
Grand Cayman,
P.O. Box 10250,
Cayman Islands, and

(iii) Waqas Khatri
55 Post Rd West, 2nd Floor
Westport, CT 06880

(c) **Citizenship:**

- (i) Ayrton Capital LLC: United States;
- (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: Cayman Islands; and
- (iii) Waqas Khatri: United States

(d) **Title of class of securities:**

Common Stock, \$0.0001 par value

(e) **CUSIP No.:**

71715X203

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) **Amount beneficially owned:**

- (i) Ayrton Capital LLC: 774,100;
- (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 774,100; and
- (iii) Waqas Khatri: 774,100.

Represents 774,100 shares of Common Stock issuable on the exercise of certain warrants (the "Warrants") held by the Reporting Persons. The issuable shares of Common Stock related to the exercise of the Warrants are both subject to either a 4.99% or a 9.99% beneficial ownership blocker.

Shares reported herein represent Common Stock of PharmaCyte Biotech, Inc. (the "Issuer") held by Alto Opportunity Master Fund, SPC- Segregated Master Portfolio B, a Cayman Islands exempted company (the "Fund"). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the "Investment Manager"), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the "Reporting Persons").

(b) Percent of class:

The percentages below are based on (i) 6,968,134 shares of Common Stock of the Issuer that were outstanding as of December 9, 2024; and (ii) 774,100 shares of Common Stock issuable on the exercise of the Warrants held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer's Form 10-Q, filed on December 13, 2024. For the sake of clarity, the holdings of the Reporting Persons reported herein are as of December 31, 2024.

- (i) Ayrton Capital LLC: 9.9%;
- (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 9.9%; and
- (iii) Waqas Khatri: 9.9% %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

- (i) Ayrton Capital LLC: 774,100;
- (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 774,100; and
- (iii) Waqas Khatri: 774,100

(ii) Shared power to vote or to direct the vote:

- (i) Ayrton Capital LLC: 0;
- (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0;
- (iii) Waqas Khatri: 0

(iii) Sole power to dispose or to direct the disposition of:

- (i) Ayrton Capital LLC: 774,100;
- (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 774,100; and
- (iii) Waqas Khatri: 774,100

(iv) Shared power to dispose or to direct the disposition of:

- (i) Ayrton Capital LLC: 0;
- (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; and
- (iii) Waqas Khatri: 0

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ayrton Capital LLC

Signature: /s/ Waqas Khatri
Name/Title: Waqas Khatri / Managing Member
Date: 02/13/2025

Alto Opportunity Master Fund, SPC -
Segregated Master Portfolio B

Signature: /s/ Waqas Khatri
Name/Title: Waqas Khatri / Director
Date: 02/13/2025

Waqas Khatri

Signature: /s/ Waqas Khatri
Name/Title: Waqas Khatri
Date: 02/13/2025